Thermo Fisher Scientific Inc. (NYSE:TMO) Given Average Recommendation of "Moderate Buy" by Analysts

Shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Get Free Report) have earned a consensus recommendation of "Moderate Buy" from the twenty-one brokerages that are presently covering the stock, MarketBeat reports. Four research analysts have rated the stock with a hold recommendation and seventeen have issued a buy recommendation on the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $647.43.

A number of equities analysts have issued reports on TMO shares. Wells Fargo & Company raised their target price on Thermo Fisher Scientific from $660.00 to $680.00 and gave the stock an "overweight" rating in a report on Friday, January 31st. StockNews.com raised shares of Thermo Fisher Scientific from a "hold" rating to a "buy" rating in a research note on Tuesday, January 14th. UBS Group boosted their price target on shares of Thermo Fisher Scientific from $700.00 to $715.00 and gave the company a "buy" rating in a report on Friday, January 31st. Barclays dropped their price objective on Thermo Fisher Scientific from $620.00 to $475.00 and set an "equal weight" rating on the stock in a research note on Thursday. Finally, Royal Bank of Canada set a $693.00 price target on Thermo Fisher Scientific in a report on Friday, January 31st.

Remove Ads

Insider Buying and Selling at Thermo Fisher Scientific

In other news, SVP Michael A. Boxer sold 3,775 shares of the business's stock in a transaction dated Monday, March 10th. The shares were sold at an average price of $532.52, for a total transaction of $2,010,263.00. Following the transaction, the senior vice president now directly owns 10,816 shares in the company, valued at $5,759,736.32. The trade was a 25.87 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, EVP Gianluca Pettiti sold 300 shares of the firm's stock in a transaction dated Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now owns 16,363 shares of the company's stock, valued at $9,582,009.17. This trade represents a 1.80 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 23,900 shares of company stock worth $13,106,062 over the last ninety days. 0.34% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Thermo Fisher Scientific

Large investors have recently added to or reduced their stakes in the business. Norges Bank bought a new stake in shares of Thermo Fisher Scientific during the fourth quarter worth approximately $3,149,754,000. GAMMA Investing LLC lifted its holdings in Thermo Fisher Scientific by 60,610.9% during the 1st quarter. GAMMA Investing LLC now owns 2,419,331 shares of the medical research company's stock worth $1,203,859,000 after purchasing an additional 2,415,346 shares during the last quarter. T. Rowe Price Investment Management Inc. grew its holdings in Thermo Fisher Scientific by 86.9% in the 4th quarter. T. Rowe Price Investment Management Inc. now owns 3,083,900 shares of the medical research company's stock valued at $1,604,338,000 after buying an additional 1,433,444 shares in the last quarter. Kovitz Investment Group Partners LLC increased its position in Thermo Fisher Scientific by 1,905.4% during the 4th quarter. Kovitz Investment Group Partners LLC now owns 903,232 shares of the medical research company's stock worth $469,889,000 after buying an additional 858,193 shares during the period. Finally, Proficio Capital Partners LLC lifted its holdings in shares of Thermo Fisher Scientific by 68,617.0% during the fourth quarter. Proficio Capital Partners LLC now owns 762,759 shares of the medical research company's stock worth $396,810,000 after buying an additional 761,649 shares in the last quarter. Institutional investors own 89.23% of the company's stock.

Thermo Fisher Scientific Stock Performance

Thermo Fisher Scientific stock traded up $10.45 during trading hours on Friday, hitting $448.60. The stock had a trading volume of 2,370,499 shares, compared to its average volume of 1,701,499. Thermo Fisher Scientific has a fifty-two week low of $409.85 and a fifty-two week high of $627.88. The company has a quick ratio of 1.29, a current ratio of 1.66 and a debt-to-equity ratio of 0.59. The company has a 50-day moving average of $510.56 and a two-hundred day moving average of $538.78. The company has a market cap of $169.24 billion, a PE ratio of 27.14, a price-to-earnings-growth ratio of 2.99 and a beta of 0.86.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, equities research analysts anticipate that Thermo Fisher Scientific will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Investors of record on Friday, March 14th will be given a dividend of $0.43 per share. The ex-dividend date of this dividend is Friday, March 14th. This is a boost from Thermo Fisher Scientific's previous quarterly dividend of $0.39. This represents a $1.72 annualized dividend and a yield of 0.38%. Thermo Fisher Scientific's dividend payout ratio is 10.41%.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.